LA
NBIX icon

LBP AM’s Neurocrine Biosciences NBIX Stock Holding History

LBP AM’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Buy
1,724
+144
+9% +$19.1K ﹤0.01% 385
2025
Q4 		$224K Sell
1,580
-737
-32% -$107K ﹤0.01% 406
2025
Q3 		$325K Hold
2,317
– – ﹤0.01% 379
2025
Q2 		$291K Hold
2,317
– – ﹤0.01% 363
2025
Q1 		$256K Sell
2,317
-22,816
-91% -$2.89M ﹤0.01% 360
2024
Q4 		$3.43M Sell
25,133
-4,733
-16% -$585K 0.05% 232
2024
Q3 		$3.44M Buy
29,866
+22,883
+328% +$3.14M 0.05% 212
2024
Q2 		$961K Buy
6,983
+383
+6% +$52.5K 0.04% 233
2024
Q1 		$910K Buy
+6,600
New +$901K 0.04% 257
2023
Q1 		– Sell
-1,820
Closed -$217K – 474
2022
Q4 		$217K Buy
+1,820
New +$213K 0.01% 449

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LBP AM's NBIX Position: Q1 2026 in Review

LBP AM increased its Neurocrine Biosciences (NBIX) stake by 9.1% in Q1 2026, buying an estimated $19.1K and bringing the position to 1,724 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #385.

LBP AM first reported a position in NBIX in Q4 2022 and has held it in 10 quarters since. The position peaked at $3.44M in Q3 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • LBP AM held 1,724 shares of Neurocrine Biosciences worth $227K as of Q1 2026.
  • LBP AM bought 144 Neurocrine Biosciences shares in Q1 2026, an estimated $19.1K.
  • Neurocrine Biosciences made up ﹤0.01% of LBP AM's portfolio in Q1 2026, its #385 holding.
  • LBP AM first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 10 quarters since.
  • LBP AM's Neurocrine Biosciences position peaked at $3.44M in Q3 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on LBP AM's 13F filing for Q1 2026, filed 27 Apr 2026.